A Pilot Study of Automated Pupillometry in the Treatment of Opioid Use Disorder

被引:3
作者
Peeler, Crandall E. [1 ,2 ]
Gorgy, Merit [1 ]
Sadlak, Natalie [1 ]
Sathe, Shaleen [1 ]
Tamashunas, Nina [1 ]
Fiorello, Marissa G. [1 ]
Cabral, Howard [3 ]
Paasche-Orlow, Michael K. [4 ]
Weinstein, Zoe M. [4 ]
机构
[1] Boston Univ, Sch Med, Boston Med Ctr, Dept Ophthalmol, Boston, MA 02118 USA
[2] Boston Univ, Sch Med, Boston Med Ctr, Dept Neurol, Boston, MA 02118 USA
[3] Boston Univ, Sch Med, Boston Med Ctr, Dept Biostat, Boston, MA 02118 USA
[4] Boston Univ, Sch Med, Boston Med Ctr, Dept Med, Boston, MA 02118 USA
关键词
opioid use disorder; opioid withdrawal; pupillometry; OPIATE WITHDRAWAL; PUPIL SIZE; METHADONE; DETOXIFICATION;
D O I
10.1097/ADM.0000000000000794
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Introduction/Background: A rough, visual estimate of pupil size is used in grading the severity of opioid withdrawal. Few studies have examined the clinical utility of more precise automated pupillometry measurements. Methods: This prospective cohort study enrolled 27 patients receiving opioid agonist therapy (OAT) to treat cravings or withdrawal during an acute hospitalization. Six sets of automated pupillometry measurements were obtained at regular intervals before and after administration of OAT. Clinical Opiate Withdrawal Scale measurements were performed pre and post OAT. Primary outcomes included pupil size in dark and bright illumination (mm). Latency of the pupillary light response (s), constriction and dilation velocity (mm/s), and percent constriction (%) were secondary outcomes. Results: The mean predosing pupil size in dark and bright illumination was 4.33 +/- 1.40 mm and 2.96 +/- 0.79 mm, respectively. A significantly decreased mean pupil size was first detected at 15 minutes postdosing (4.01 +/- 1.34 mm, P = 0.0115 for dark illumination; 2.71 +/- 0.72 mm, P = 0.0003 for bright illumination) and this reduction in pupil size persisted at later postdosing timepoints. Those with Clinical Opiate Withdrawal Scale <5 after dosing had a greater decrease in dark pupil size (10.6% +/- 13.2 vs 3.2% +/- 3.2, P = 0.043). There was no significant change in the remaining pupil reactivity parameters. Conclusions: Automated pupillometry demonstrated a small but significant change in mean pupil size that occurred within 15 minutes of OAT dosing and was associated with low withdrawal scores. This pilot may inform future work to incorporate pupillometry measurement into OAT dosing assessments.
引用
收藏
页码:477 / 483
页数:7
相关论文
共 50 条
  • [41] Factors associated with cognitive flexibility in people with opioid-use disorder: a pilot study
    Regier, Paul S.
    de Arruda, Thais Costa Macedo
    Sinko, Laura
    Teitelman, Anne M.
    Childress, Anna Rose
    [J]. FRONTIERS IN PSYCHIATRY, 2024, 15
  • [42] Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder
    Thakrar, Ashish P.
    Uritsky, Tanya J.
    Christopher, Cara
    Winston, Anna
    Ronning, Kaitlin
    Sigueza, Anna Lee
    Caputo, Anne
    McFadden, Rachel
    Olenik, Jennifer M.
    Perrone, Jeanmarie
    Delgado, M. Kit
    Lowenstein, Margaret
    Compton, Peggy
    [J]. ADDICTION SCIENCE & CLINICAL PRACTICE, 2023, 18 (01)
  • [43] Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder
    Ashish P. Thakrar
    Tanya J. Uritsky
    Cara Christopher
    Anna Winston
    Kaitlin Ronning
    Anna Lee Sigueza
    Anne Caputo
    Rachel McFadden
    Jennifer M. Olenik
    Jeanmarie Perrone
    M. Kit Delgado
    Margaret Lowenstein
    Peggy Compton
    [J]. Addiction Science & Clinical Practice, 18
  • [44] An uncontrolled pilot trial of a buprenorphine dispensing device to enhance outpatient treatment for Opioid Use Disorder
    Wenzel, Kevin
    Thomas, Julia
    Davis, Michael
    Saenko, Maria
    Ervin, Matthew
    Machineni, Praveena
    Rudin, Lauren
    Fishman, Marc
    [J]. HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, 2023, 25 (05) : 7 - 11
  • [45] "The elephant in the room;" a qualitative study of perinatal fears in opioid use disorder treatment in Southern Appalachia
    Leiner, Catherine
    Cody, Tamara
    Mullins, Nathan
    Ramage, Melinda
    Ostrach, Bayla M. M.
    [J]. BMC PREGNANCY AND CHILDBIRTH, 2021, 21 (01)
  • [46] Recent Advances in the Treatment of Opioid Use Disorder
    Sumanth Kuppalli
    Raghav Seth
    Vwaire Orhurhu
    Ivan Urits
    Alan D. Kaye
    Corey Hunter
    Amitabh Gulati
    Peju Adekoya
    Adam M. Kaye
    Mark R. Jones
    [J]. Current Pain and Headache Reports, 2021, 25
  • [47] Management of Opioid Use Disorder Treatment An Overview
    Salmond, Susan
    Allread, Virginia
    Marsh, Robert
    [J]. ORTHOPAEDIC NURSING, 2019, 38 (02) : 118 - 126
  • [48] Opioid Use Disorder: Medical Treatment Options
    Coffa, Diana
    Snyder, Hannah
    [J]. AMERICAN FAMILY PHYSICIAN, 2019, 100 (07) : 416 - 425
  • [49] Barriers to treatment for opioid use disorder in Colombia
    Borda, Juan P.
    Friedman, Hannah
    Buitrago, Jhon
    Isaza, Maritza
    Herrera, Paula
    Krawczyk, Noa
    Tofighi, Babak
    [J]. JOURNAL OF SUBSTANCE USE, 2021, 26 (06) : 632 - 638
  • [50] Pharmacological treatment of opioid use disorder in pregnancy
    Rodriguez, Christina E.
    Klie, Kaylin A.
    [J]. SEMINARS IN PERINATOLOGY, 2019, 43 (03) : 141 - 148